Cancer immunotherapy for prostate cancer.
Our approach to prostate cancer immunotherapy involves two components dendritic cells as antigen-presenting cells; and the antigen used to target T-cell attack, HLA-A0201-associated peptides from prostate specific membrane antigen (PSMA). We have conducted a phase I dose-ranging study in 51 men with advanced prostate cancer, using dendritic cells pulsed with a PSMA peptide. no significant toxicity was observed. In that study, T-cell response was enhanced, with seven men meeting NCPC and PSA criteria for partial response. We are now conducting a phase II study with 67 men, who will receive 6 infusions of dendritic cells that have been pulsed with 2 PSMA peptides, at 6-week intervals. The phase II study design and rationale is described in this paper.
B. A.
BA
Tjoa
S. J.
SJ
Erickson
V. A.
VA
Bowes
M. L.
ML
Salgaller
P. A.
PA
Lodge
J. G.
JG
McLean
H.
H
Ragde
G. M.
GM
Kenny
A. L.
AL
Boynton
G. P.
GP
Murphy